Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPS15AP19 (ribosomal protein S15a pseudogene 19) is classified as a processed pseudogene, not a canonical protein-coding gene or therapeutic target. RPS15AP19 (ribosomal protein S15a pseudogene 19) is annotated as a processed pseudogene of the ribosomal protein S15a gene. Pseudogenes are genomic DNA sequences similar to known genes but generally nonfunctional due to disablements such as frame-shift mutations or premature stop codons. They do not encode functional proteins and are not considered druggable therapeutic targets. RPS15AP19 was identified based on sequence homology and is one of many pseudogenes derived from ribosomal protein gene families that are scattered throughout the human genome. Most pseudogenes, including RPS15AP19, have little or no functional protein product, and their biological roles, if any, are usually confined to potential regulatory effects at the RNA level, which remain
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein S15a pseudogene 19 (RPS15AP19).